Mizuho Financial Group, Inc. Sponosred ADR (Japan) (MFG)

Total Costs & Expenses

¥7.16T

TTM · Period ending: · JPY

MFG logo

MFG Total Costs & Expenses

Latest reported¥7.16T JPY
MFG TTM Total Costs & Expenses · JPY (¥4.01T → ¥7.16T)
High-resolution chart · PNG

MFG total costs & expenses history

Trailing twelve months (TTM) · JPY. Each value covers four complete reported quarters.

Mizuho Financial Group, Inc. Sponosred ADR (Japan) Total Costs & Expenses — Trailing twelve months (TTM) (JPY)
Period endingTotal Costs & Expenses (JPY)
7,159,083,969,000
7,034,234,941,000
6,982,312,000,000
7,193,601,000,000
7,289,216,000,000
7,574,166,000,000
7,876,240,000,000
7,451,093,000,000
7,361,584,000,000
6,900,957,000,000
6,165,210,000,000
5,664,147,000,000
4,932,934,000,000
4,108,711,000,000
3,220,038,000,000
2,772,599,000,000
2,427,981,000,000
2,231,139,000,000
2,224,259,000,000
2,076,187,000,000
2,057,759,000,000
2,234,587,000,000
2,363,714,000,000
2,637,946,000,000
2,856,749,000,000
2,961,691,000,000
3,793,530,000,000
3,470,459,000,000
3,388,717,000,000
3,371,537,000,000
2,431,522,000,000
2,625,927,000,000
2,717,819,000,000
2,628,226,000,000
3,482,319,000,000
3,107,261,000,000
2,563,760,000,000
2,221,851,000,000
1,206,649,000,000
1,481,365,000,000
1,706,648,000,000
1,622,849,000,000
1,636,798,000,000
1,699,841,000,000
1,639,957,000,000
1,895,882,000,000
1,861,420,000,000
1,697,863,000,000
1,670,289,000,000
1,646,411,000,000
1,732,565,000,000
1,810,191,000,000
1,742,275,000,000
1,784,710,000,000
1,386,137,000,000
1,575,073,000,000
1,678,248,000,000
1,736,564,000,000
1,860,175,000,000
1,746,816,000,000
1,787,541,000,000
1,764,393,000,000
1,544,153,000,000
1,720,897,000,000
1,777,775,000,000
2,051,200,000,000
2,294,487,972,700
2,471,443,926,020
2,646,999,926,020
2,763,717,926,020
3,097,048,443,270
3,193,895,077,070
3,508,101,613,800
3,510,155,613,800
4,007,052,367,160
3,769,118,654,500
3,541,033,738,280
3,255,369,605,880
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.